ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

exagamglogene autotemcel

Also written as “CTX001”, “Exa-cel” and “CTX001 With and Without Iron”.

Its studies are mostly in beta-Thalassemia · Anemia, Sickle Cell · Renal Insufficiency, Chronic · Anemia, led by 2 companies.

Drug pageExagamglogene autotemcel: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 29, 20189 company-led studies, 6 open or runningNext primary completion: Jun 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals74 open or runningphase 3since Aug 29, 2018Aug 29, 2018Jun 6, 2027phase 3 · NCT05329649
Cajal Therapeuticsits history only22 open or runningphase 1since Oct 22, 2026May 5, 2026Oct 2027phase 1 · NCT07901933

Also a collaborator on its studies: CRISPR Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vertex Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2018First study: phase 3 study in beta-ThalassemiaFirst studyNCT03655678 · 59 enrolled · United States, Canada, Germany and more
  2. Nov 9, 2018Phase 3 study in Anemia, Sickle CellNCT03745287 · 63 enrolled · United States, Belgium, Canada and more
  3. Dec 20, 2019Phase 3 study in beta-ThalassemiaNCT04208529 · 160 planned · United States, Belgium, Canada and more
  4. Dec 19, 2020Named exagamglogene autotemcelINNProposed as its International Nonproprietary Name in WHO's List 124 · before, CTX001
  5. Apr 7, 20222 phase 3 studiesNCT05356195, NCT05329649
  6. Jul 26, 2022Phase 3 study in beta-ThalassemiaNCT05477563 · 26 planned · United States, Germany, Italy and more
  7. Jun 23, 2023Phase 3 study in Anemia, Sickle CellNCT05951205

Ahead

  1. Jun 6, 2027Primary completion: phase 3 study in Anemia, Sickle CellNCT05329649
  2. Jun 9, 2027Primary completion: phase 3 study in beta-ThalassemiaNCT05477563
  3. Nov 14, 2027Primary completion: phase 3 study in beta-ThalassemiaNCT05356195
  4. Sep 30, 2039Primary completion: phase 3 study in beta-ThalassemiaNCT04208529

TargetBeta

BCL11A →read by rule
“B-cell lymphoma/leukemia 11A gene editing negative modulator”ChEMBL 37, by rule

Studies

All 7 Vertex Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05951205Anemia, Sickle Cell3WithdrawnDec 31, 20330
NCT05477563beta-Thalassemia · United States, Germany, Italy and more3RecruitingJun 9, 202726
NCT05356195beta-Thalassemia · United States, Canada, Germany and more3Active, not recruitingNov 14, 202716
NCT05329649Anemia, Sickle Cell · United States, Germany, Italy and more3Active, not recruitingJun 6, 202713
NCT04208529beta-Thalassemia · United States, Belgium, Canada and more3By invitationSep 30, 2039160
NCT03745287Anemia, Sickle Cell · United States, Belgium, Canada and more3CompletedJul 7, 202563
NCT03655678beta-Thalassemia · United States, Canada, Germany and more3CompletedNov 13, 202559

How it is read

Names in the registry

  • “CTX001”, 6 entries
  • “Exa-cel”, 2 entries
  • “CTX001 With and Without Iron”, 1 entry
  • “CTX001 With Iron”, 1 entry
  • “CTX001 Multiple Dose”, 1 entry

Codes read as this program: CTX001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.